Thermo Fisher Scientific ( TMO -0.6% ) will report Q3 results on October 22 before the open. The conference call will begin at 8:30 am ET. Consensus view is EPS of $1.69 on revenues of $4.22B. Post your comment!
Thermo Fisher Scientific (NYSE: TMO ) enters into an agreement with GlaxoSmithKline (NYSE: GSK ..... diagnostic for multiple drug programs. The test will be based on Thermo 's Ion Personal Genome Machine Dx Platform , Ion AmpliSeq technology
nearly double Merck’s academic and research lab segment, making the company a significant contender among peers like Thermo Fisher . Although growth in this market has been challenged by global budget pressure on research spending, we think reasonably
selling at or near the top of the PE range of the last ten years. However, other quality names such as Thermo Fisher Scientific (NYSE: TMO ) or Saint Jude Medical (NYSE: STJ ) are comfortably in the middle of their historical ranges. The
04 14,864 3 ThermoFisher TMO 2 Medium Narrow 120.21 1.12 48 ..... Monsanto, and narrow-moat Thermo Fisher Scientific TMO and Noble Energy NBL --were from ..... involved in the purchases of both Thermo Fisher Scientific and PepsiCo, the former being
Medium 13,755 1 ThermFishr TMO 2 Narrow 121.55 1.14 Medium ..... of Schlumberger (SLB) and Thermo Fisher Scientific ( TMO ), noting the following about ..... quarter--Schlumberger, Thermo Fisher Scientific , and W.W. Grainger. Oilfield
Thermo Fisher Scientific 's second-quarter results were ..... is the biggest uncertainty for the Thermo Fisher 's outlook in the second half. The ..... continued operating improvements. Thermo Fisher also raised its Life Sciences cost
Cemex SAB de CV Thermo Fisher Scientific Economic Moat ..... Ratio*: 0.75 Thermo Fisher Scientific TMO is the product of the merger between Thermo Electron and Fisher ..... Analyst Report: Thermo Fisher Scientific Walt Disney Economic
We are dropping coverage of Life Technologies as it has been successfully acquired by Thermo Fisher Scientific following regulatory approval and is no longer a publicly traded company.
offset sluggish genetic analysis sales. In light of Thermo Fisher 's definitive agreement to acquire the company for ..... delivering third-quarter EPS growth of 10%. In light of Thermo Fisher 's acquisition, Life no longer provides quarterly